clinical trial · NCT03911739
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
T. John Winhusen, PhD·—·completed·n = 71
Opioid-Related DisordersDrug AddictionPregnancy RelatedSubstance AbuseDrug AbuseNeonatal Abstinence SyndromeNeonatal Opiate Withdrawal SyndromeDrug Abuse in PregnancyBuprenorphine InjectionBuprenorphine Sublingual Product
brief summary
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1). Caretakers of the infants delivered by MOMs participants will be offered the opportunity to enroll in this sub-study, which is designed to evaluate the impact of extended-release buprenorphine (BUP-XR), relative to sublingual buprenorphine (BUP-SL), on infant neurodevelopment. The additional data collected in this sub-study will be combined with data from the main MOMs trial.
started
Jun 14, 2021
primary completion
Dec 30, 2024
completion
Dec 30, 2024
last updated
Mar 16, 2026
official title
NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): Infant Neurodevelopmental Outcomes (INO) Sub-study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol